Portfoliotracker

Evommune, Inc.

EVMN · NYSE · Healthcare Biotechnology 7/100 E

7,100 $
▼ −0,530 (−6,95 %)
Pre-market delayed by 20 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:34
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score7 / 100 Market cap258 mil. $ P/E0,6 Forward P/E-2,0 P/S– P/B1,0 EV/EBITDA– Dividend yield– FCF yield-35,28 % EPS-3,83 $ Net margin0,0 % Return on equity-69,5 % Beta– Debt / equity0,03
52-week range 4,94 to 33,20
3-month average volume0,8 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Employees
48
Country
United States
Fiscal year end
31. 12.
Data since
6. 11. 2025

Explore further

Similar companies MPLTALMSMAZELBRXSION

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account